First Ascent Biomedical Responds to ASCO Clarification on Functional Precision Medicine
News
Right to Try has given patients with life-threatening illnesses a pathway to access investigational drugs after approved options and clinical…
Our study shows the technical feasibility of integrating functional precision medicine approaches for patients with refractory/relapsed pediatric cancers. Routine clinical…
Our studies demonstrate the potential for predictive and generative artificial intelligence and machine learning approaches to address critical challenges multi-omics,…
First Ascent Biomedical Inc., a clinical-stage functional precision medicine company advancing the novel xDRIVE (Ex Vivo Drug Response Identification and…
Inside Precision Medicine April 18, 2024 IPM interviewed Dr. Diana Azzam First Ascent co-founder and cancer researcher about her latest…
Risk or presence of metastasis in medulloblastoma causes substantial treatment-related morbidity and overall mortality. Read the full publication on PubMed.
Systemic therapy for metastatic clear cell sarcoma (CCS) bearing EWSR1-CREB1/ATF1 fusions remains an unmet clinical need in children, adolescents, and…
Over the past 25 years, chemotherapy regimens for osteosarcoma have failed to improve the 65-70% long-term survival rate. Radiation therapy…
Metastatic epithelioid sarcoma (EPS) remains a largely unmet clinical need in children, adolescents and young adults despite the advent of…